|
|
|
0 members (),
492
guests, and
24
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
1
|
2
|
3
|
4
|
5
|
6
|
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
|
|
|
|
|
|
There are no members with birthdays on this day. |
#378760
Thu 02 Jun 2016 07:18:PM
|
Joined: Feb 2001
Posts: 381,903
Launch Director
|
OP
Launch Director
Joined: Feb 2001
Posts: 381,903 |
A new cancer treatment called CD40 inhibitor has yielded disappointing results when tested in clinical trials, failing to mobilize patients' immune system against tumors the way it was expected to. But a recent study offers clues about how this experimental drug might be optimized to fulfill its potential. Source: New mouse models give a boost to the development of cancer immunotherapies
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics684,257
Posts718,866
Members2,957
| |
Most Online3,142
Jan 16th, 2023
|
|
|
|
|
Copyright 1996 - 2023 by David Cottle. Designed by David Bate Jr. All Rights Reserved.
By using this forum, the user agrees not to transfer any data or technical information received under the agreement, to any other entity without the express approval of the AUS-CITY Forum Admins and/or authors of individual posts (Forum Admins and DoD/USSPACECOM for the analysis of satellite tracking data).
Two-line elements (TLE) and all other satellite data presented and distributed via this forum and e-mail lists of AUS-CITY are distributed with permission from DoD/USSTRATCOM.
Reprise Hosting
|
|
